Ultime notizie per Gaotu Techedu (NYSE:GOTU) Azioni

Gaotu Techedu

Gaotu Techedu Inc is a technology-driven education company that provides online live courses in a large-class setting backed by its proprietary technology infrastructure. The company's segment includes the provision of education services. The company offers courses in large-class format, which amplifies the benefits of online education and allows it to rapidly expand its student base. It operates solely in the PRC and all assets are located in the PRC. The learning services that the company offers include Traditional Learning Services, Non-Academic Tutoring Services, and College Student and Adult Education Services.

GSX Techedu

Gaotu Techedu Inc. American Depositary Shares

Gaotu Techedu Inc

Gain Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that an oral presentation as well as a poster were presented at the&nbsp;<a href="https://www.globenewswire.com/Tracker?data=vGaHtetDNz_zeU7j37II4m-QXG8fY1eTo96jO1aptZzJPE5uwGaKBIy182yIaOe4HfgMYH3QvLs8vjI1m-XmQ56_nBEdAZGhJGn3l6wtpZ-hBk_ZAkjEr1nQ-_yQzT4oVlviXeKTBPLocdRy3AJDE9W78P3mUfiCITL28ff3G53ZpfjZSn6RlIEHn4s3SDPtSvTzuiO_ufqGEyOwAD_uwnMJO5cAEo75OQgGTVcJEE22NvpEmgN-_NYdsoOODAGuC0_VTkkh1ddtg7DpMNaYYNHJ77hme6cOg0gNApzEIlS6Cjsee8IpwWwwTox1cqwV6UZ7ZyTpJjfvBFeE26C3UiLa0j8gfw-m1epnHzJJnvQb3GA3ZDplXbdku9TiAysXMlbFux4oAAqFclLnnE6NZGhn5SiYcsCDp85o9mUn9R7p_3OgYwcYG1u223keBpYW6-cT6WZEs_24r07cSMV5tH1EID-FlOFTlYSnpy7eUHIeBsA0GPutAdWwHK-ET3gO7kW3BXRSSrgWDf7vsXaYoNtHU7KSFTXEOsKKAe5I7l5Q7XpwFYEm7EtLlvs22VOLpoJSqouZ8Tcjq2qL4qfm2fEJqKbDThd8i5tNXyAJijcQGVbXG-7uC8cFGBGcVYPNg-2mkPzfZn3W55A0gjkLQF1RRImBqrY0LLaD8EWoYMzF3EwTSQHtzv1LkTApIoLw7gs2PADSufqdLhWmx_rE4jI-6NxMFzq8cOUWGZDNnr__i4dtiwNMOtrtfCAS1YWkzPLay_dJd0FiYqGF8E5F2Zf7sNhPfNpqV_hXm5bxP_QHVoLKgDfZLUWCOx2jhp4c">AD/PD&#x2122; 2025 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders</a> held April 1-5, 2025, in Vienna, Austria. The oral presentation outlined new evidence further supporting the disease-modifying activity of GT-02287 in preclinical models of both GBA1 and idiopathic Parkinson's disease (PD). Additionally, the poster presented detailed the design of the ongoing Phase 1b clinical study of GT-02287 in people with Parkinson's disease.
An early biomarker analysis from the currently enrolled participants in the Phase 1b study will be conducted mid-year and will include samples from participants both with and without the GBA1 mutations for purposes of informing Phase 2 planning during the second half of 2025. Complete analysis of the Phase 1b endpoints, available after all patients have completed 90 days of treatment, is anticipated sometime during the fourth quarter of 2025.

News

GANX

Gain Therapeutics Targets Phase 2 as GT-02287 Phase 1b Biomarker Readout Set for Mid-2025

Goldman Sachs analyst Kash Rangan upgrades BorgWarner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) from Neutral to Buy and raises the price target from $31 to $34.

Upgrades

Price Target

Analyst Ratings

Goldman Sachs Upgrades BorgWarner to Buy, Raises Price Target to $34

Needham analyst Joseph Stringer reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and maintains $35 price target.

Reiteration

CDTX

Needham Reiterates Buy on Cidara Therapeutics, Maintains $35 Price Target

Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) reported quarterly earnings of $2.13 per share which beat the analyst consensus estimate of $1.87 by 13.9 percent. This is a 13.9 percent increase over earnings of $1.87 per share from the same period last year. The company reported quarterly sales of $241.490 million which beat the analyst consensus estimate of $233.954 million by 3.22 percent. This is a 3.60 percent decrease over sales of $250.507 million the same period last year.

Earnings

Earnings Beats

LOVE

Lovesac Q4 2025 GAAP EPS $2.13 Beats $1.87 Estimate, Sales $241.490M Beat $233.954M Estimate

CLMB

Climb Channel Solutions Partners With Thales To Expand Cybersecurity Offerings

Goldman Sachs analyst Mark Delaney downgrades Visteon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) from Buy to Neutral and lowers the price target from $103 to $74.

Downgrades

Goldman Sachs Downgrades Visteon to Neutral, Lowers Price Target to $74

In an episode of Amazon's The Grand Tour, host Jeremy Clarkson stirred debate over how self-driving cars should respond in life-or-death situations. In a conversation with co-hosts James May and Richard Hammond, Clarkson posed a stark question: If an autonomous vehicle must decide between veering into a group of pedestrians or endangering its own passenger, whose life should it prioritize?
What To Know: That quandary, often called the "trolley problem," has shifted from a philosophical exercise to an urgent engineering puzzle. As per a <a href="https://archive.curbed.com/2016/10/18/13313282/driverless-cars-safety-mercedes-pedestrian">report</a> by Curbed, industry heavyweights such as Mercedes-Benz, Tesla, and Waymo now face intense scrutiny over how their systems should respond in unavoidable crash situations. Although Mercedes made headlines in 2016 for seemingly hinting it would prioritize driver safety, the company later clarified it seeks "the highest possible level of safety for all road users."
Most <a href="http://Jeremy Clarkson's 'Trolley Problem' Question About Driverless Cars From Ages Ago Continues To Pose A Moral Dilemma For Auto Makers">autonomous car firms</a> emphasize accident avoidance rather than pre-programmed trade-offs. Per a separate <a href="https://www.vox.com/recode/22700022/self-driving-autonomous-cars-trolley-problem-waymo-google-tesla">report</a> by Vox, Waymo, for example, has logged over 20 million real-world miles without an at-fault fatal crash, largely through a conservative driving style that aims to prevent dire choices before they arise. Meanwhile, Tesla's "Full Self-Driving" remains in beta testing with drivers expected to supervise at all times, effectively leaving last-second moral calls in human hands.
See also: <a href="https://www.benzinga.com/25/04/44730103/us-bike-prices-set-to-soar-amid-escalating-china-trade-war">Uber Teams Up With WeRide To Bring Self-Driving Cars To Dubai</a>
<h3 class="wp-block-heading">What Does Public Opinion Veer Towards?</h3>
Researchers at the Massachusetts Institute of Technology have <a href="https://news.mit.edu/2018/how-autonomous-vehicles-programmed-1024#:~:text=The%20survey%20has%20global%20reach,a%20large%20group%20of%20bystanders">explored</a> public opinion on these dilemmas through a project known as the "Moral Machine," gathering millions of votes on how a driverless car should act when faced with grim alternatives. Among the findings: Most participants prefer saving more lives over fewer, with a slight bias toward younger pedestrians.
<h3 class="wp-block-heading">Legalities Remain Murky And Confused</h3>
Legal frameworks remain murky. Germany, for instance, has declared it illegal for an autonomous system to discriminate among people in a crash. Elsewhere, regulators have yet to offer definitive guidance on whether responsibility lies with the manufacturer, software developer, or passenger.
Featured Image via Shutterstock
Read next: <a href="https://www.benzinga.com/general/space/25/04/44730104/trumps-nasa-chief-pick-isaacman-tells-senate-we-will-prioritize-sending-american-astronauts-to-mars">Trump&#8217;s NASA Nominee Jared Isaacman Tells Senate &#8216;We Will Prioritize Sending American Astronauts to Mars&#8217;</a>

Entertainment

Tech

General

Jeremy Clarkson's 'Trolley Problem' Question About Driverless Cars From Ages Ago Continues To Pose A Moral Dilemma For Auto Makers

Needham analyst Mike Matson reiterates Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) with a Buy and maintains $7 price target.

PSNL

Needham Reiterates Buy on Personalis, Maintains $7 Price Target

RCAT

Red Cat Holdings Launches $30M Offering; Proceeds Aimed At Working Capital And Corporate Use

Goldman Sachs analyst Mark Delaney downgrades Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) from Buy to Neutral and lowers the price target from $117 to $84.

Goldman Sachs Downgrades Lear to Neutral, Lowers Price Target to $84

Buybacks

ITT Intents To Repurchase Up To $500M Shares

<ul>
<li>Orders of $1.0 billion, reflecting growth of 7% or 2% on an organic basis, driven by pump project and connectors awards</li>
<li>Revenue of more than $900 million; flat on a GAAP and organic basis, driven by strength in pumps aftermarket, connectors and rail, offset by lower aerospace demand</li>
<li>Operating margin of 16.5% and adjusted operating margin of 17.4%, impacted by unfavorable foreign currency</li>
<li>Earnings per share (EPS) of $1.29 to $1.35 and adjusted EPS of $1.43 to $1.45</li>
<li>Net cash from operating activities of $107 million to $117 million and free cash flow of $70 million to $80 million</li>
</ul>

Guidance

ITT Released Preliminary Q1 2025 Sales Of Over $900M Vs. Consensus Of $901.06M, With Adjusted EPS $1.43-$1.45 Vs. Consensus Of $1.43

Needham analyst Serge Belanger reiterates Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) from Hold to Hold.

AMPH

Needham Reiterates Hold on Amphastar Pharmato Hold

Goldman Sachs analyst Mark Delaney downgrades Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) from Buy to Neutral and lowers the price target from $11 to $9.

Goldman Sachs Downgrades Ford Motor to Neutral, Lowers Price Target to $9

Goldman Sachs analyst Matt Greene upgrades ArcelorMittal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MT#NYSE">MT</a>) from Neutral to Buy and raises the price target from $29 to $31.7.

Goldman Sachs Upgrades ArcelorMittal to Buy, Raises Price Target to $31.7

Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) with a Buy and maintains $12 price target.

IMRX

Needham Reiterates Buy on Immuneering, Maintains $12 Price Target

B of A Securities analyst Craig Siegenthaler upgrades Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) from Neutral to Buy and maintains the price target from $65 to $65.

B of A Securities Upgrades Brookfield Asset Mgmt to Buy, Maintains Price Target to $65

<ul>
<li>Combined business to be renamed Elevra Lithium upon merger completion</li>
<li>Elevra Lithium Board of Directors Nominees named with four members from each standalone business select</li>
</ul>

Piedmont Lithium And Sayona Mining To Merge As Elevra Lithium; Board Nominees Announced

B of A Securities analyst Joshua Dennerlein initiates coverage on MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) with a Neutral rating and announces Price Target of $585.

Initiation

MSCI

B of A Securities Initiates Coverage On MSCI with Neutral Rating, Announces Price Target of $585

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Edgewise Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>)</h3>
<ul>
<li>On April 2, Edgewise Therapeutics priced an underwritten public offering of 9.94 million shares at $20.13 per share, expecting to raise approximately $200 million. The offering is set to close on April 3, pending customary conditions. The company's stock fell around 55% over the past month and has a 52-week low of $10.60.</li>
<li>RSI Value: 27.5</li>
<li>EWTX Price Action: Shares of Edgewise Therapeutics gained 8.8% to close at $12.50 on Wednesday.</li>
<li>Edge Stock Ratings: 15.43 Momentum score. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/ewtx"><img loading="lazy" decoding="async" width="493" height="173" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043318/image-59.png" alt="" class="wp-image-865422" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043318/image-59.png 493w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043318/image-59-300x105.png 300w" sizes="(max-width: 493px) 100vw, 493px" /></a></figure>
<h3 class="wp-block-heading">Genfit SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Feb. 7, HC Wainwright &amp; Co. analyst Ed Arce reiterated Genfit with a Buy rating and maintained a $13 price target. The company's stock fell around 27% over the past five days and <a href="https://www.benzinga.com/quote/GNFT">has a 52-week low</a> of $2.55.</li>
<li>RSI Value: 29.3</li>
<li>GNFT Price Action: Shares of Genfit dipped 21.4% to close at $2.64 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410">GNFT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410"><img loading="lazy" decoding="async" width="921" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60.png" alt="" class="wp-image-865424" style="width:597px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60.png 921w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60-768x694.png 768w" sizes="(max-width: 921px) 100vw, 921px" /></a></figure>
<h3 class="wp-block-heading">CAMP4 Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>)</h3>
<ul>
<li>On March 27, CalAmp reported a quarterly loss of $11.04 per share which met the analyst consensus estimate. &#8220;We are off to a strong start in 2025, building on the momentum of a successful 2024, which included advancing our Phase 1 clinical program in UCDs, establishing key research collaborations, securing important regulatory designations, and completing our initial public offering,&#8221; said Josh Mandel-Brehm, Chief Executive Officer of CAMP4. The company's stock fell around 49% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/CAMP">low of $0.39.</a></li>
<li>RSI Value: 23.1</li>
<li>CAMP Price Action: Shares of CAMP4 Therapeutics dipped 7.4% to close at $2.14 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410">CAMP shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410"><img loading="lazy" decoding="async" width="886" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61.png" alt="" class="wp-image-865425" style="width:416px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61.png 886w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61-768x716.png 768w" sizes="(max-width: 886px) 100vw, 886px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

CAMP

EWTX

GNFT

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

Press Releases

Gaotu Techedu to Report First Quarter 2024 Financial Results on May 21, 2024

Gaotu Techedu Announces First Quarter 2024 Unaudited Financial Results

Gaotu Techedu to Report Second Quarter 2024 Financial Results on August 27, 2024

Gaotu Techedu Announces Second Quarter 2024 Unaudited Financial Results

Technical Explosions: DUO, KTTA, TBIO, GOTU – Watch Peraso Inc. (NASDAQ: PRSO) Now Amid Breakout Momentum!

Gaotu Techedu to Report Third Quarter 2024 Financial Results on December 4, 2024

Gaotu Techedu Announces Third Quarter 2024 Unaudited Financial Results

Gaotu Techedu to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 26, 2025

Gaotu Techedu Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results

Gaotu Techedu Projects a Meaningful Reduction in Non-GAAP Operating Loss for 2025

GOTU

KTTA

PRSO

TBIO

Afya

American Public Education, Inc. - Common Stock

American Public Education

Adtalem Global Education Inc. Common Stock

Adtalem Glb Education

Bright Horizons Family Solutions Inc. Common Stock

Bright Horizons Family

China Liberal Education Holdings Limited - Ordinary Shares

China Liberal Education

Coursera

Youdao, Inc. American Depositary Shares, each representing one Class A Ordinary Share

Youdao

Duolingo

New Oriental Education & Technology Group, Inc. Sponsored ADR representing 10 Ordinary Share (Cayman Islands)

Comments

Gaotu Techedu

Notizie

Ultime notizie per Gaotu Techedu (NYSE:GOTU) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO